Citation: Zerui Yang, Jingyan Zeng, Yueyue Chen, Mengchun Wang, Hongchun Luo, Ai-Long Huang, Haijun Deng, Yuan Hu. Detection of HBV DNA integration in plasma cell-free DNA of different HBV diseases utilizing DNA capture strategy .VIROLOGICA SINICA, 2024, 39(4) : 655-666.  http://dx.doi.org/10.1016/j.virs.2024.06.003

Detection of HBV DNA integration in plasma cell-free DNA of different HBV diseases utilizing DNA capture strategy

cstr: 32224.14.j.virs.2024.06.003
  • The landscape of hepatitis B virus (HBV) integration in the plasma cell-free DNA (cfDNA) of HBV-infected patients with different stages of liver diseases [chronic hepatitis B (CHB), liver cirrhosis (LC), and hepatocellular carcinoma (HCC)] remains unclear. In this study, we developed an improved strategy for detecting HBV DNA integration in plasma cfDNA, based on DNA probe capture and next-generation sequencing. Using this optimized strategy, we successfully detected HBV integration events in chimeric artificial DNA samples and HBV-infected HepG2-NTCP cells at day one post infection, with high sensitivity and accuracy. The characteristics of HBV integration events in the HBV-infected HepG2-NTCP cells and plasma cfDNA from HBV-infected individuals (CHB, LC, and HCC) were further investigated. A total of 112 and 333 integration breakpoints were detected in the HepG2-NTCP cells and 22 out of 25 (88%) clinical HBV-infected samples, respectively. In vivo analysis showed that the normalized number of support unique sequences (nnsus) in HCC was significantly higher than in CHB or LC patients (P values < 0.05). All integration breakpoints are randomly distributed on human chromosomes and are enriched in the HBV genome around nt 1800. The majority of integration breakpoints (61.86%) are located in the gene-coding region. Both non-homologous end-joining (NHEJ) and microhomology-mediated end-joining (MMEJ) interactions occurred during HBV integration across the three different stages of liver diseases. Our study provides evidence that HBV DNA integration can be detected in the plasma cfDNA of HBV-infected patients, including those with CHB, LC, or HCC, using this optimized strategy.

  • 加载中
  • 10.1016j.virs.2024.06.003-ESM.docx
    1. Bertoletti A, Ferrari C. 2016. Adaptive immunity in hbv infection. J Hepatol, 64: S71-s83.

    2. Bouffard P, Lamelin JP, Zoulim F, Pichoud C, Trepo C. 1990. Different forms of hepatitis b virus DNA and expression of hbv antigens in peripheral blood mononuclear cells in chronic hepatitis b. J Med Virol, 31: 312-317.

    3. Budzinska MA, Shackel NA, Urban S, Tu T. 2018a. Cellular genomic sites of hepatitis b virus DNA integration. Genes (Basel), 9.

    4. Budzinska MA, Shackel NA, Urban S, Tu T. 2018b. Sequence analysis of integrated hepatitis b virus DNA during hbeag-seroconversion. Emerg Microbes Infect, 7: 142.

    5. Cai J, Chen L, Zhang Z, Zhang X, Lu X, Liu W, Shi G, Ge Y, Gao P, Yang Y, Ke A, Xiao L, Dong R, Zhu Y, Yang X, Wang J, Zhu T, Yang D, Huang X, Sui C, Qiu S, Shen F, Sun H, Zhou W, Zhou J, Nie J, Zeng C, Stroup EK, Zhang X, Chiu BC, Lau WY, He C, Wang H, Zhang W, Fan J. 2019. Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma. Gut, 68: 2195-2205.

    6. Chauhan R, Churchill ND, Mulrooney-Cousins PM, Michalak TI. 2017. Initial sites of hepadnavirus integration into host genome in human hepatocytes and in the woodchuck model of hepatitis b-associated hepatocellular carcinoma. Oncogenesis, 6: e317.

    7. Chauhan R, Shimizu Y, Watashi K, Wakita T, Fukasawa M, Michalak TI. 2019. Retrotransposon elements among initial sites of hepatitis b virus integration into human genome in the hepg2-ntcp cell infection model. Cancer Genet, 235-236: 39-56.

    8. Chen W, Zhang K, Dong P, Fanning G, Tao C, Zhang H, Guo S, Wang Z, Hong Y, Yang X, Lai S, Ding H, Zhao H, Zeng C, Protzer U, Zhang D. 2020. Noninvasive chimeric DNA profiling identifies tumor-originated hbv integrants contributing to viral antigen expression in liver cancer. Hepatol Int, 14: 326-337.

    9. Chen X, Kost J, Sulovari A, Wong N, Liang WS, Cao J, Li D. 2019. A virome-wide clonal integration analysis platform for discovering cancer viral etiology. Genome Res, 29: 819-830.

    10. Chen Y, Shen B, Zheng X, Long Q, Xia J, Huang Y, Cai X, Wang D, Chen J, Tang N, Huang A, Hu Y. 2020. Dhx9 interacts with apobec3b and attenuates the anti-hbv effect of apobec3b. Emerg Microbes Infect, 9: 366-377.

    11. Dong H, Zhang L, Qian Z, Zhu X, Zhu G, Chen Y, Xie X, Ye Q, Zang J, Ren Z, Ji Q. 2015. Identification of hbv-mll4 integration and its molecular basis in chinese hepatocellular carcinoma. PLoS One, 10: e0123175.

    12. Erken R, Loukachov V, van Dort K, van den Hurk A, Takkenberg RB, de Niet A, Jansen L, Willemse S, Reesink H, Kootstra N. 2022. Quantified integrated hepatitis b virus is related to viral activity in patients with chronic hepatitis b. Hepatology, 76: 196-206.

    13. Gao N, Guan G, Xu G, Wu H, Xie C, Mo Z, Deng H, Xiao S, Deng Z, Peng L, Lu F, Zhao Q, Gao Z. 2023. Integrated hbv DNA and cccdna maintain transcriptional activity in intrahepatic hbsag-positive patients with functional cure following peg-ifn-based therapy. Aliment Pharmacol Ther, 58: 1086-1098.

    14. Gong SS, Jensen AD, Chang CJ, Rogler CE. 1999. Double-stranded linear duck hepatitis b virus (dhbv) stably integrates at a higher frequency than wild-type dhbv in lmh chicken hepatoma cells. J Virol, 73: 1492-1502.

    15. Grudda T, Hwang HS, Taddese M, Quinn J, Sulkowski MS, Sterling RK, Balagopal A, Thio CL. 2022. Integrated hepatitis b virus DNA maintains surface antigen production during antiviral treatment. J Clin Invest, 132.

    16. Hino O, Ohtake K, Rogler CE. 1989. Features of two hepatitis b virus (hbv) DNA integrations suggest mechanisms of hbv integration. J Virol, 63: 2638-2643.

    17. Hu JL, Huang AL. 2024. Classifying hepatitis B therapies with insights from covalently closed circular DNA dynamics. Virol Sin, 39: 9-23.

    18. Jang JW, Kim JS, Kim HS, Tak KY, Nam H, Sung PS, Bae SH, Choi JY, Yoon SK, Roberts LR. 2021. Persistence of intrahepatic hepatitis b virus DNA integration in patients developing hepatocellular carcinoma after hepatitis b surface antigen seroclearance. Clin Mol Hepatol, 27: 207-218.

    19. Li CL, Li CY, Lin YY, Ho MC, Chen DS, Chen PJ, Yeh SH. 2019. Androgen receptor enhances hepatic telomerase reverse transcriptase gene transcription after hepatitis b virus integration or point mutation in promoter region. Hepatology, 69: 498-512.

    20. Li CL, Ho MC, Lin YY, Tzeng ST, Chen YJ, Pai HY, Wang YC, Chen CL, Lee YH, Chen DS, Yeh SH, Chen PJ. 2020. Cell-free virus-host chimera DNA from hepatitis b virus integration sites as a circulating biomarker of hepatocellular cancer. Hepatology, 72: 2063-2076.

    21. Li W, Zeng X, Lee NP, Liu X, Chen S, Guo B, Yi S, Zhuang X, Chen F, Wang G, Poon RT, Fan ST, Mao M, Li Y, Li S, Wang J, Jianwang, Xu X, Jiang H, Zhang X. 2013. Hivid: An efficient method to detect hbv integration using low coverage sequencing. Genomics, 102: 338-344.

    22. Lin SY, Su YP, Trauger ER, Song BP, Thompson EGC, Hoffman MC, Chang TT, Lin YJ, Kao YL, Cui Y, Hann HW, Park G, Shieh FS, Song W, Su YH. 2021. Detection of hepatitis b virus-host junction sequences in urine of infected patients. Hepatol Commun, 5: 1649-1659.

    23. Lin YY, Hsieh CH, Chen JH, Lu X, Kao JH, Chen PJ, Chen DS, Wang HY. 2017. De novo assembly of highly polymorphic metagenomic data using in situ generated reference sequences and a novel blast-based assembly pipeline. BMC Bioinformatics, 18: 223.

    24. Luo H, Wei W, Ye Z, Zheng J, Xu RH. 2021. Liquid biopsy of methylation biomarkers in cell-free DNA. Trends Mol Med, 27: 482-500.

    25. Luo X, Huang Y, Chen Y, Tu Z, Hu J, Tavis JE, Huang A, Hu Y. 2016. Association of hepatitis b virus covalently closed circular DNA and human apobec3b in hepatitis b virus-related hepatocellular carcinoma. PLoS One, 11: e0157708.

    26. Marzese DM, Hirose H, Hoon DS. 2013. Diagnostic and prognostic value of circulating tumor-related DNA in cancer patients. Expert Rev Mol Diagn, 13: 827-844.

    27. Mason WS, Jilbert AR, Litwin S. 2021. Hepatitis b virus DNA integration and clonal expansion of hepatocytes in the chronically infected liver. Viruses, 13.

    28. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M, DePristo MA. 2010. The genome analysis toolkit: A mapreduce framework for analyzing next-generation DNA sequencing data. Genome Res, 20: 1297-1303.

    29. Meier MA, Calabrese D, Suslov A, Terracciano LM, Heim MH, Wieland S. 2021. Ubiquitous expression of hbsag from integrated hbv DNA in patients with low viral load. J Hepatol, 75: 840-847.

    30. Mladenov E, Magin S, Soni A, Iliakis G. 2016. DNA double-strand-break repair in higher eukaryotes and its role in genomic instability and cancer: Cell cycle and proliferation-dependent regulation. Semin Cancer Biol, 37-38: 51-64.

    31. Murakami Y, Minami M, Daimon Y, Okanoue T. 2004. Hepatitis b virus DNA in liver, serum, and peripheral blood mononuclear cells after the clearance of serum hepatitis b virus surface antigen. J Med Virol, 72: 203-214.

    32. Nguyen MH, Wong G, Gane E, Kao JH, Dusheiko G. 2020. Hepatitis b virus: Advances in prevention, diagnosis, and therapy. Clin Microbiol Rev, 33.

    33. Pannunzio NR, Watanabe G, Lieber MR. 2018. Nonhomologous DNA end-joining for repair of DNA double-strand breaks. J Biol Chem, 293: 10512-10523.

    34. Pollicino T, Caminiti G. 2021. Hbv-integration studies in the clinic: Role in the natural history of infection. Viruses, 13.

    35. Revill P, Testoni B, Locarnini S, Zoulim F. 2016. Global strategies are required to cure and eliminate hbv infection. Nat Rev Gastroenterol Hepatol, 13: 239-248.

    36. Saigo K, Yoshida K, Ikeda R, Sakamoto Y, Murakami Y, Urashima T, Asano T, Kenmochi T, Inoue I. 2008. Integration of hepatitis b virus DNA into the myeloid/lymphoid or mixed-lineage leukemia (mll4) gene and rearrangements of mll4 in human hepatocellular carcinoma. Hum Mutat, 29: 703-708.

    37. Schluter V, Meyer M, Hofschneider PH, Koshy R, Caselmann WH. 1994. Integrated hepatitis b virus x and 3' truncated pres/s sequences derived from human hepatomas encode functionally active transactivators. Oncogene, 9: 3335-3344.

    38. Skidmore ZL, Wagner AH, Lesurf R, Campbell KM, Kunisaki J, Griffith OL, Griffith M. 2016. Genvisr: Genomic visualizations in r. Bioinformatics, 32: 3012-3014.

    39. Song A, Lin X, Chen X. 2021. Functional cure for chronic hepatitis b: Accessibility, durability, and prognosis. Virol J, 18: 114.

    40. Sung WK, Zheng H, Li S, Chen R, Liu X, Li Y, Lee NP, Lee WH, Ariyaratne PN, Tennakoon C, Mulawadi FH, Wong KF, Liu AM, Poon RT, Fan ST, Chan KL, Gong Z, Hu Y, Lin Z, Wang G, Zhang Q, Barber TD, Chou WC, Aggarwal A, Hao K, Zhou W, Zhang C, Hardwick J, Buser C, Xu J, Kan Z, Dai H, Mao M, Reinhard C, Wang J, Luk JM. 2012. Genome-wide survey of recurrent hbv integration in hepatocellular carcinoma. Nat Genet, 44: 765-769.

    41. Treangen TJ, Salzberg SL. 2011. Repetitive DNA and next-generation sequencing: Computational challenges and solutions. Nat Rev Genet, 13: 36-46.

    42. Tu T, Budzinska MA, Shackel NA, Urban S. 2017. Hbv DNA integration: Molecular mechanisms and clinical implications. Viruses, 9.

    43. Tu T, Budzinska MA, Vondran FWR, Shackel NA, Urban S. 2018. Hepatitis b virus DNA integration occurs early in the viral life cycle in an in vitro infection model via sodium taurocholate cotransporting polypeptide-dependent uptake of enveloped virus particles. J Virol, 92.

    44. van Buuren N, Ramirez R, Soulette C, Suri V, Han D, May L, Turner S, Parvangada PC, Martin R, Chan HLY, Marcellin P, Buti M, Bui N, Bhardwaj N, Gaggar A, Li L, Mo H, Feierbach B. 2022. Targeted long-read sequencing reveals clonally expanded hbv-associated chromosomal translocations in patients with chronic hepatitis b. JHEP Rep, 4: 100449.

    45. Wang Q, Jia P, Zhao Z. 2015. Verse: A novel approach to detect virus integration in host genomes through reference genome customization. Genome Med, 7: 2.

    46. Wooddell CI, Yuen MF, Chan HL, Gish RG, Locarnini SA, Chavez D, Ferrari C, Given BD, Hamilton J, Kanner SB, Lai CL, Lau JYN, Schluep T, Xu Z, Lanford RE, Lewis DL. 2017. Rnai-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis b virus DNA is a source of hbsag. Sci Transl Med, 9.

    47. Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, Feng T, Zhou L, Tang W, Zhan L, Fu X, Liu S, Bo X, Yu G. 2021. Clusterprofiler 4.0: A universal enrichment tool for interpreting omics data. Innovation (Camb), 2: 100141.

    48. Yang W, Summers J. 1995. Illegitimate replication of linear hepadnavirus DNA through nonhomologous recombination. J Virol, 69: 4029-4036.

    49. Yang W, Summers J. 1999. Integration of hepadnavirus DNA in infected liver: Evidence for a linear precursor. J Virol, 73: 9710-9717.

    50. Yeh SH, Li CL, Lin YY, Ho MC, Wang YC, Tseng ST, Chen PJ. 2023. Hepatitis b virus DNA integration drives carcinogenesis and provides a new biomarker for hbv-related hcc. Cell Mol Gastroenterol Hepatol, 15: 921-929.

    51. Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, Kawaguchi T, Kurosaki M, Sakaida I, Shimizu M, Taniai M, Terai S, Nishikawa H, Hiasa Y, Hidaka H, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K. 2021. Evidence-based clinical practice guidelines for liver cirrhosis 2020. J Gastroenterol, 56: 593-619.

    52. You H, Wang F, Li T, Xu X, Sun Y, Nan Y, Wang G, Hou J, Duan Z, Wei L, Jia J, Zhuang H, Chinese Society of Hepatology CMA, Chinese Society of Infectious Diseases CMA. 2023. Guidelines for the prevention and treatment of chronic hepatitis b (version 2022). J Clin Transl Hepatol, 11: 1425-1442.

    53. Zhang M, Zhang H, Cheng X, Wang X, Xu H, Gao X, Wu R, Zhang D, Xia Y, Niu J. 2022. Liver biopsy of chronic hepatitis b patients indicates hbv integration profile may complicate the endpoint and effect of entecavir treatment. Antiviral Res, 204: 105363.

    54. Zhao LH, Liu X, Yan HX, Li WY, Zeng X, Yang Y, Zhao J, Liu SP, Zhuang XH, Lin C, Qin CJ, Zhao Y, Pan ZY, Huang G, Liu H, Zhang J, Wang RY, Yang Y, Wen W, Lv GS, Zhang HL, Wu H, Huang S, Wang MD, Tang L, Cao HZ, Wang L, Lee TL, Jiang H, Tan YX, Yuan SX, Hou GJ, Tao QF, Xu QG, Zhang XQ, Wu MC, Xu X, Wang J, Yang HM, Zhou WP, Wang HY. 2016. Genomic and oncogenic preference of hbv integration in hepatocellular carcinoma. Nat Commun, 7: 12992.

    55. Zheng B, Liu XL, Fan R, Bai J, Wen H, Du LT, Jiang GQ, Wang CY, Fan XT, Ye YN, Qian YS, Wang YC, Liu GJ, Deng GH, Shen F, Hu HP, Wang H, Zhang QZ, Ru LL, Zhang J, Gao YH, Xia J, Yan HD, Liang MF, Yu YL, Sun FM, Gao YJ, Sun J, Zhong CX, Wang Y, Kong F, Chen JM, Zheng D, Yang Y, Wang CX, Wu L, Hou JL, Liu JF, Wang HY, Chen L. 2021. The landscape of cell-free hbv integrations and mutations in cirrhosis and hepatocellular carcinoma patients. Clin Cancer Res, 27: 3772-3783.

    56. Zhou J, Sun H, Wang Z, Cong W, Zeng M, Zhou W, Bie P, Liu L, Wen T, Kuang M, Han G, Yan Z, Wang M, Liu R, Lu L, Ren Z, Zeng Z, Liang P, Liang C, Chen M, Yan F, Wang W, Hou J, Ji Y, Yun J, Bai X, Cai D, Chen W, Chen Y, Cheng W, Cheng S, Dai C, Guo W, Guo Y, Hua B, Huang X, Jia W, Li Q, Li T, Li X, Li Y, Li Y, Liang J, Ling C, Liu T, Liu X, Lu S, Lv G, Mao Y, Meng Z, Peng T, Ren W, Shi H, Shi G, Shi M, Song T, Tao K, Wang J, Wang K, Wang L, Wang W, Wang X, Wang Z, Xiang B, Xing B, Xu J, Yang J, Yang J, Yang Y, Yang Y, Ye S, Yin Z, Zeng Y, Zhang B, Zhang B, Zhang L, Zhang S, Zhang T, Zhang Y, Zhao M, Zhao Y, Zheng H, Zhou L, Zhu J, Zhu K, Liu R, Shi Y, Xiao Y, Zhang L, Yang C, Wu Z, Dai Z, Chen M, Cai J, Wang W, Cai X, Li Q, Shen F, Qin S, Teng G, Dong J, Fan J. 2023. Guidelines for the diagnosis and treatment of primary liver cancer (2022 edition). Liver Cancer, 12: 405-444.

  • 加载中

Figures(1)

Article Metrics

Article views(927) PDF downloads(2) Cited by()

Related
Proportional views

    Detection of HBV DNA integration in plasma cell-free DNA of different HBV diseases utilizing DNA capture strategy

      Corresponding author: Ai-Long Huang, ahuang@cqmu.edu.cn
      Corresponding author: Haijun Deng, pepper027@163.com
      Corresponding author: Yuan Hu, huyuan@cqmu.edu.cn
    • a. Key Laboratory of Molecular Biology on Infectious Diseases, Ministry of Education, Chongqing Medical University, Chongqing, 400016, China;
    • b. Department of Infectious Diseases, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China

    Abstract: The landscape of hepatitis B virus (HBV) integration in the plasma cell-free DNA (cfDNA) of HBV-infected patients with different stages of liver diseases [chronic hepatitis B (CHB), liver cirrhosis (LC), and hepatocellular carcinoma (HCC)] remains unclear. In this study, we developed an improved strategy for detecting HBV DNA integration in plasma cfDNA, based on DNA probe capture and next-generation sequencing. Using this optimized strategy, we successfully detected HBV integration events in chimeric artificial DNA samples and HBV-infected HepG2-NTCP cells at day one post infection, with high sensitivity and accuracy. The characteristics of HBV integration events in the HBV-infected HepG2-NTCP cells and plasma cfDNA from HBV-infected individuals (CHB, LC, and HCC) were further investigated. A total of 112 and 333 integration breakpoints were detected in the HepG2-NTCP cells and 22 out of 25 (88%) clinical HBV-infected samples, respectively. In vivo analysis showed that the normalized number of support unique sequences (nnsus) in HCC was significantly higher than in CHB or LC patients (P values < 0.05). All integration breakpoints are randomly distributed on human chromosomes and are enriched in the HBV genome around nt 1800. The majority of integration breakpoints (61.86%) are located in the gene-coding region. Both non-homologous end-joining (NHEJ) and microhomology-mediated end-joining (MMEJ) interactions occurred during HBV integration across the three different stages of liver diseases. Our study provides evidence that HBV DNA integration can be detected in the plasma cfDNA of HBV-infected patients, including those with CHB, LC, or HCC, using this optimized strategy.

    Figure (1)  Reference (56) Relative (20)

    目录

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return